HS-20093

HS-20093 is an investigational agent whose form is not stated in the registry developed by Hansoh BioMedical R&D and Jiangsu HengRui Medicine. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Participants in all subjucts will receive HS-20093 at 10mg/kg. It is the investigational product in 6 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06935409 (Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure) and NCT06498479 (ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer), in osteosarcoma, non-small-cell lung cancer, sarcomas, prostate cancer and head and neck squamous cell carcinoma. The largest, NCT06498479, plans to enrol 460 participants with primary completion expected 2026-09-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.